The most useful questions to ask before MOTS-c cover the goal, current medicines, medical history and follow-up. The provider also needs to explain which findings came from mice. Published human treatment results cannot yet predict what MOTS-c will do for a person.

These ten questions help make the visit specific. Each explains something the provider needs to know, and the evidence behind asking.

Questions to ask before MOTS-c: the evidence

1. What problem are we trying to address, and which studies match it?

The provider needs the actual concern: tiredness, blood sugar, training or something else. Those goals aren't interchangeable.

MOTS-c is a peptide, a short chain of protein building blocks, encoded by mitochondria, the cell's energy-making parts. In Lee and colleagues' 2015 Cell Metabolism study, treatment findings about weight and the response to insulin came from mice. Insulin is the hormone that helps control blood sugar. The paper explains the interest; it doesn't establish a human treatment result.

2. What has giving MOTS-c to people actually shown?

As of October 29, 2026, the day this article was written, MOTS-MET's record, last updated April 1, 2026, lists recruiting status and 120 planned participants. It has no posted results. Participants have prediabetes, blood sugar above normal but below the diabetes range, and overweight or obesity.

The trial compares MOTS-c with placebo, an inactive treatment, over 12 weeks. Main measures are insulin sensitivity, how readily the body responds to insulin, and unwanted health events through week 16. Its Matsuda index is a calculation from a blood-sugar challenge test. A study plan cannot establish benefit or side-effect rates.

As of October 29, 2026, the day this article was written, an HHS notice filed October 28 announces a nonbinding draft policy covering six peptides, including MOTS-c. The policy describes enforcement discretion: HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding one of the six when all ten conditions are met; the HHS policy explainer covers those conditions.

In July 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding MOTS-c to the list of ingredients pharmacies may compound with (the review history); that advice concerned compounding ingredients, rather than a finished medicine. MOTS-c has no FDA-approved drug product in the United States. MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

Medicines and medical history

3. How do my medicines and other peptides affect the discussion?

The provider needs the complete list, including metformin, insulin, supplements and other peptides such as SS-31. Separate studies of individual ingredients don't establish a combination's safety.

MOTS-MET excludes recent use of medicines that lower blood sugar, including metformin. That leaves combinations unanswered. The mouse insulin findings explain why the provider asks about low-blood-sugar episodes, but don't establish a human interaction. The MOTS-c and metformin discussion examines that specific gap. A trial exclusion isn't an instruction to stop an existing medicine.

4. What do kidney or liver problems change?

Diagnoses, recent test results and current care help the provider understand the starting point. The trial's eligibility criteria exclude substantially reduced kidney function and significant liver disease.

With no posted results, it cannot establish safety for those groups. Nor does it provide a tested adjustment for someone whose organs process medicines differently. The reason for asking is missing evidence, rather than a known MOTS-c complication.

5. Why does current or past cancer matter?

The review needs the diagnosis, treatment dates and ongoing cancer care. The same trial excludes active cancer requiring treatment, apart from adequately treated non-melanoma skin cancer.

In cell and mouse studies, MOTS-c changed how cells handle energy. That makes cancer history relevant to a review of an incompletely studied treatment; it doesn't show that MOTS-c causes cancer. The broader peptide-and-cancer discussion explains why different molecules raise different questions. A past diagnosis needs individual consideration, rather than a borrowed warning from another drug.

Pregnancy and earlier reactions

6. What does pregnancy, planning pregnancy or breastfeeding change?

The MOTS-MET trial excludes all three. That means its eventual results won't establish pregnancy or breastfeeding safety. These details belong in the history because the available human evidence cannot answer them.

As of October 29, 2026, the day this article was written, an October 2026 Reproduction and Fertility paper examines human ovary-support cells and mouse eggs in laboratory experiments. It did not test treatment in pregnant people or live-birth outcomes. Findings about cells that support eggs cannot establish that taking MOTS-c is safe while trying to conceive.

7. How do earlier allergic reactions affect the review?

The provider asks what product caused the reaction, what happened and how soon afterward. A persistent lump, hives and breathing trouble describe different patterns.

FDA's evaluation dated May 11, 2026 identifies missing human safety data and possible immune reactions linked to peptide clumping or impurities. These are concerns, rather than measured MOTS-c reaction rates. MOTS-MET also excludes known allergies to peptide treatments or preparation ingredients and tracks antibodies, proteins the immune system makes against a target.

Training goals and sport rules

8. Does the exercise research match my training goal?

The provider needs the activity, training load and the change being sought. A request about endurance differs from one about unexplained tiredness.

In Reynolds and colleagues' 2021 Nature Communications study, ten men exercised while researchers measured the MOTS-c their bodies made. They weren't given the peptide. Treatment experiments were in mice. The MOTS-c exercise guide separates those findings; they don't establish that a prescription improves a person's workout.

9. Am I covered by anti-doping rules?

Competition details matter even when sport is a hobby. A prescription alone doesn't settle sport eligibility.

As of October 29, 2026, the day this article was written, the 2026 World Anti-Doping Agency list names MOTS-c as “prohibited at all times.” WADA's 2027 list, published September 21, retains that restriction from January 1, 2027. Section S4.4.1 covers substances that activate AMPK, a cell's energy-sensing switch. These are sport rules, separate from a medical prescribing decision.

Progress needs a starting point

10. What would count as progress, and what would lead to stopping?

The visit needs a starting measure, a review date and a contact for concerns. The registered trial chooses blood-sugar measures and records unwanted health events. Its calendar isn't an established treatment duration for everyone.

A provider can explain which measures fit the concern, what change would matter and which symptoms require prompt contact. New symptoms, a changed diagnosis or no meaningful progress can lead to reassessment or stopping. Changing several treatments together also makes it harder to identify what caused a change.

At Promise, a licensed provider reviews every request, and not everyone qualifies.